Patented technology applied in SynGEM, a needle-free nasal spray vaccine against respiratory syncytial virus
Re-Issuance of U.S. Patent No. RE 47,471 further bolsters Mucosis’ intellectual property portfolio
Groningen / Odijk, The Netherlands, July 2, 2019 – The trustee of biotech company Mucosis B.V., Mr. Holtz LLM and Virtuvax B.V. today announce that the US Patent Office (USPTO) has issued patent RE. 47,471 dated July 2, 2019. The patent is a reissue of Mucosis’ US Patent No. 9,060,975 (“reset patent”). The granted patent contains twenty-five claims including thirteen original as well as modified claims of the reset patent plus twelve additi...